

Carla Oliveira

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1600301/carla-oliveira-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

181
papers

12,592
citations

55
h-index

110
g-index

191
ext. papers

14,791
ext. citations

6.7
avg, IF

5.76
L-index

#	Paper	IF	Citations
181	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD.. <i>European Journal of Medical Genetics</i> , 2022 , 104475	2.6	0
180	Upregulation of tRNA-Ser-AGA-2-1 Promotes Malignant Behavior in Normal Bronchial Cells.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 809985	5.6	
179	Comparison of East-Asia and West-Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness. <i>International Journal of Cancer</i> , 2021 , 150, 868	7.5	0
178	Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes. <i>European Journal of Medical Genetics</i> , 2021 , 65, 104401	2.6	1
177	Genetic and Epigenetic Alterations of Regulatory Regions in Hereditary and Sporadic Gastric Cancer. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	5
176	The role of non-standard translation in <i>Candida albicans</i> pathogenesis. <i>FEMS Yeast Research</i> , 2021 , 21,	3.1	1
175	Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. <i>Molecular Oncology</i> , 2021 , 15, 2841-2867	7.9	9
174	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. <i>European Journal of Human Genetics</i> , 2021 , 29, 1354-1358	5.3	5
173	Solving patients with rare diseases through programmatic reanalysis of genome-phenome data. <i>European Journal of Human Genetics</i> , 2021 , 29, 1337-1347	5.3	4
172	Redefinition of familial intestinal gastric cancer: clinical and genetic perspectives. <i>Journal of Medical Genetics</i> , 2021 , 58, 1-11	5.8	10
171	Towards Automatic Protein Co-Expression Quantification in Immunohistochemical TMA Slides. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2021 , 25, 393-402	7.2	0
170	Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells. <i>Nanomaterials</i> , 2021 , 11,	5.4	5
169	A Fast Alternative to Soft Lithography for the Fabrication of Organ-on-a-Chip Elastomeric-Based Devices and Microactuators. <i>Advanced Science</i> , 2021 , 8, 2003273	13.6	5
168	tRNAs as a Driving Force of Genome Evolution in Yeast. <i>Frontiers in Microbiology</i> , 2021 , 12, 634004	5.7	0
167	The c.1901C>T Variant: A Founder Variant in the Portuguese Population with Severe Impact in mRNA Splicing. <i>Cancers</i> , 2021 , 13,	6.6	3
166	Cancer predisposition and germline CTNNA1 variants. <i>European Journal of Medical Genetics</i> , 2021 , 64, 104316	2.6	5
165	Updated perspective and directions on hereditary diffuse gastric cancer 2021 , 217-258		1

164	Proteomics Analysis of Gastric Cancer Patients with Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	12
163	Immunophenotype of Gastric Tumors Unveils a Pleiotropic Role of Regulatory T Cells in Tumor Development. <i>Cancers</i> , 2021 , 13,	6.6	1
162	Germline Testing in Breast Cancers: Why, When and How?. <i>Cancers</i> , 2020 , 12,	6.6	7
161	Effective intracellular delivery of bevacizumab via PEGylated polymeric nanoparticles targeting the CD44v6 receptor in colon cancer cells. <i>Biomaterials Science</i> , 2020 , 8, 3720-3729	7.4	9
160	Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. <i>European Journal of Human Genetics</i> , 2020 , 28, 1379-1386	5.3	61
159	Risk-reducing total gastrectomy in asymptomatic CDH1 carriers. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2020 , 52, 171-178	0.9	1
158	The Dysfunctional Immune System in Common Variable Immunodeficiency Increases the Susceptibility to Gastric Cancer. <i>Cells</i> , 2020 , 9,	7.9	4
157	Inherited CDH1 pathogenic variant: is there a place for surveillance of esophageal gastric inlet patch?. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820916399	4.7	
156	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology</i> , 2020 , 21, e386-e397	21.7	95
155	Reply to Kratz et al. <i>European Journal of Human Genetics</i> , 2020 , 28, 1483-1485	5.3	3
154	Skipping Exon-v6 from CD44v6-Containing Isoforms Influences Chemotherapy Response and Self-Renewal Capacity of Gastric Cancer Cells. <i>Cancers</i> , 2020 , 12,	6.6	2
153	Human cells adapt to translational errors by modulating protein synthesis rate and protein turnover. <i>RNA Biology</i> , 2020 , 17, 135-149	4.8	8
152	Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells. <i>Cancers</i> , 2020 , 12,	6.6	8
151	Genetics of gastric cancer: what do we know about the genetic risks?. <i>Translational Gastroenterology and Hepatology</i> , 2019 , 4, 55	5.2	19
150	Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition. <i>Cancers</i> , 2019 , 11,	6.6	15
149	tRNA Deregulation and Its Consequences in Cancer. <i>Trends in Molecular Medicine</i> , 2019 , 25, 853-865	11.5	34
148	Gastric Cancer Extracellular Vesicles Tune the Migration and Invasion of Epithelial and Mesenchymal Cells in a Histotype-Dependent Manner. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	6
147	Hereditary gastric cancer: what's new? Update 2013-2018. <i>Familial Cancer</i> , 2019 , 18, 363-367	3	27

146	CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells. <i>Cells</i> , 2019 , 8,	7.9	17
145	New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. <i>Gastric Cancer</i> , 2019 , 22, 77-90	7.6	27
144	Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. <i>Scientific Reports</i> , 2019 , 9, 10362	4.9	3
143	Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the -- Axis in Diffuse Gastric Cancer. <i>Cancers</i> , 2019 , 12,	6.6	4
142	S100P is a molecular determinant of E-cadherin function in gastric cancer. <i>Cell Communication and Signaling</i> , 2019 , 17, 155	7.5	6
141	The effects of L-carnitine supplementation in athletic performance. <i>Science and Sports</i> , 2019 , 34, 63-72	0.8	3
140	3D Cellular Architecture Affects MicroRNA and Protein Cargo of Extracellular Vesicles. <i>Advanced Science</i> , 2019 , 6, 1800948	13.6	42
139	CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer. <i>BMC Cancer</i> , 2019 , 19, 69	4.8	8
138	The effects of death and post-mortem cold ischemia on human tissue transcriptomes. <i>Nature Communications</i> , 2018 , 9, 490	17.4	108
137	CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodeling. <i>Integrative Biology (United Kingdom)</i> , 2018 , 10, 145-158	3.7	13
136	Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. <i>Gastrointestinal Endoscopy</i> , 2018 , 87, 1566-1575	5.2	32
135	Role of germline aberrations affecting , and in gastric cancer susceptibility. <i>Journal of Medical Genetics</i> , 2018 , 55, 669-674	5.8	30
134	Codon misreading tRNAs promote tumor growth in mice. <i>RNA Biology</i> , 2018 , 15, 773-786	4.8	22
133	Impact of surfactants on the target recognition of Fab-conjugated PLGA nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018 , 127, 366-370	5.7	13
132	Anti-miRNA oligonucleotides: A comprehensive guide for design. <i>RNA Biology</i> , 2018 , 15, 338-352	4.8	90
131	Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. <i>Pathobiology</i> , 2018 , 85, 50-63	3.6	63
130	Optimizing the management of hereditary haemochromatosis: the value of MRI R2* quantification to predict and monitor body iron stores. <i>British Journal of Haematology</i> , 2018 , 183, 491-493	4.5	6
129	Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. <i>Histopathology</i> , 2018 , 73, 878-886	7.3	31

128	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
127	Monoclonal antibodies: technologies for early discovery and engineering. <i>Critical Reviews in Biotechnology</i> , 2018 , 38, 394-408	9.4	44
126	Bioengineering a novel 3D in vitro model of gastric mucosa for stomach permeability studies. <i>Acta Biomaterialia</i> , 2018 , 82, 68-78	10.8	9
125	Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. <i>Acta Biomaterialia</i> , 2018 , 81, 208-218	10.8	30
124	Whole Slide Image Registration for the Study of Tumor Heterogeneity. <i>Lecture Notes in Computer Science</i> , 2018 , 95-102	0.9	4
123	Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. <i>Human Mutation</i> , 2018 , 39, 1553-1568	4.7	80
122	Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides. <i>BMC Molecular Biology</i> , 2018 , 19, 6	4.5	12
121	Rotary orbital suspension culture of embryonic stem cell-derived neural stem/progenitor cells: impact of hydrodynamic culture on aggregate yield, morphology and cell phenotype. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017 , 11, 2227-2240	4.4	4
120	Antibodies and associates: Partners in targeted drug delivery. <i>Pharmacology & Therapeutics</i> , 2017 , 177, 129-145	13.9	45
119	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. <i>European Journal of Human Genetics</i> , 2017 , 25, 1246-1252	5.3	27
118	Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer. <i>International Journal of Cancer</i> , 2017 , 141, 1478-1489	7.5	18
117	Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 908, 371-91	3.6	34
116	Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation. <i>Scientific Reports</i> , 2016 , 6, 34860	4.9	18
115	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. <i>Familial Cancer</i> , 2016 , 15, 289-96	3	10
114	Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. <i>ACS Nano</i> , 2016 , 10, 3886-99	16.7	304
113	Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicin. <i>Journal of Extracellular Vesicles</i> , 2016 , 5, 32538	16.4	46
112	A 3D in vitro model to explore the inter-conversion between epithelial and mesenchymal states during EMT and its reversion. <i>Scientific Reports</i> , 2016 , 6, 27072	4.9	41
111	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. <i>Journal of Medical Genetics</i> , 2015 , 52, 361-74	5.8	385

110	Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015 , 1852, 1928-39	6.9	50
109	Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. <i>JAMA Oncology</i> , 2015 , 1, 23-32	13.4	401
108	Hereditary cancer risk assessment: challenges for the next-gen sequencing era. <i>Frontiers in Oncology</i> , 2015 , 5, 62	5.3	2
107	KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015 , 467, 383-92	5.1	5
106	Biological properties of extracellular vesicles and their physiological functions. <i>Journal of Extracellular Vesicles</i> , 2015 , 4, 27066	16.4	2611
105	Finding and tracing human MSC in 3D microenvironments with the photoconvertible protein Dendra2. <i>Scientific Reports</i> , 2015 , 5, 10079	4.9	5
104	Familial gastric cancer: genetic susceptibility, pathology, and implications for management. <i>Lancet Oncology, The</i> , 2015 , 16, e60-70	21.7	225
103	Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy. <i>Oncotarget</i> , 2015 , 6, 30787-802	3.3	24
102	Extracellular Vesicles - Powerful Markers of Cancer Evolution. <i>Frontiers in Immunology</i> , 2014 , 5, 685	8.4	17
101	Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 464, 367-78	5.1	132
100	Hereditary diffuse gastric cancer - pathophysiology and clinical management. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 1055-68	2.5	29
99	Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. <i>European Journal of Human Genetics</i> , 2014 , 22, 1085-92	5.3	10
98	Familial gastric carcinoma. <i>Diagnostic Histopathology</i> , 2014 , 20, 239-246	0.7	4
97	Molecular characterization of ESBL-producing Enterobacteriaceae in northern Portugal. <i>Scientific World Journal, The</i> , 2014 , 2014, 782897	2.2	32
96	Germline mutations in MAP3K6 are associated with familial gastric cancer. <i>PLoS Genetics</i> , 2014 , 10, e1004669	46	
95	New target genes in endometrial tumors show a role for the estrogen-receptor pathway in microsatellite-unstable cancers. <i>Human Mutation</i> , 2014 , 35, 1514-23	4.7	8
94	Adsorbed fibrinogen enhances production of bone- and angiogenic-related factors by monocytes/macrophages. <i>Tissue Engineering - Part A</i> , 2014 , 20, 250-63	3.9	30
93	Colorectal cancer and RASSF family—a special emphasis on RASSF1A. <i>International Journal of Cancer</i> , 2013 , 132, 251-8	7.5	50

92	Gastric cancer: adding glycosylation to the equation. <i>Trends in Molecular Medicine</i> , 2013 , 19, 664-76	11.5	75
91	Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 1187-201	6.4	19
90	Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). <i>European Journal of Human Genetics</i> , 2013 , 21,	5.3	18
89	Hereditary Diffuse Gastric Cancer and Other Gastric Cancers Associated with Hereditary Predisposition Syndromes. <i>Molecular Pathology Library</i> , 2013 , 83-107		
88	E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. <i>Progress in Molecular Biology and Translational Science</i> , 2013 , 116, 337-59	4	44
87	CDX2 regulation by the RNA-binding protein MEX3A: impact on intestinal differentiation and stemness. <i>Nucleic Acids Research</i> , 2013 , 41, 3986-99	20.1	60
86	Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 868-75	2.2	128
85	Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin. <i>PLoS ONE</i> , 2013 , 8, e81579	3.7	23
84	E-Cadherin Germline Mutations 2013 , 35-49		2
83	Non-CDH1-Associated Familial Gastric Cancer and Epigenetics Factors 2013 , 111-125		
82	Alternative Mechanisms to Germline CDH1 Mutations in Hereditary Diffuse Gastric Cancer 2013 , 87-96		
81	Epithelial E- and P-cadherins: role and clinical significance in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012 , 1826, 297-311	11.2	107
80	E-cadherin dysfunction in gastric cancer--cellular consequences, clinical applications and open questions. <i>FEBS Letters</i> , 2012 , 586, 2981-9	3.8	63
79	CPEB1, a novel gene silenced in gastric cancer: a Drosophila approach. <i>Gut</i> , 2012 , 61, 1115-23	19.2	38
78	Cancer syndromes and therapy by stop-codon readthrough. <i>Trends in Molecular Medicine</i> , 2012 , 18, 667-78	11.5	50
77	Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. <i>PLoS ONE</i> , 2012 , 7, e33191	3.7	79
76	E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer. <i>PLoS ONE</i> , 2012 , 7, e33783	3.7	48
75	Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. <i>Journal of Pathology</i> , 2012 , 228, 31-44	9.4	100

74	CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. <i>International Journal of Cancer</i> , 2012 , 131, 367-76	7.5	90
73	Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. <i>Human Molecular Genetics</i> , 2012 , 21, 4253-69	5.6	14
72	Characterization of the intronic portion of cadherin superfamily members, common cancer orchestrators. <i>European Journal of Human Genetics</i> , 2012 , 20, 878-83	5.3	5
71	1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. <i>Anticancer Research</i> , 2012 , 32, 249-57	2.3	62
70	Oncogenic mutations in gastric cancer with microsatellite instability. <i>European Journal of Cancer</i> , 2011 , 47, 443-51	7.5	78
69	E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. <i>European Journal of Cancer</i> , 2011 , 47, 631-9	7.5	59
68	MSI phenotype and MMR alterations in familial and sporadic gastric cancer. <i>International Journal of Cancer</i> , 2011 , 128, 1606-13	7.5	46
67	CDH1 structural alterations as novel prognostic biomarker in gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 42-42	2.2	2
66	De novo expression of CD44 variants in sporadic and hereditary gastric cancer. <i>Laboratory Investigation</i> , 2010 , 90, 1604-14	5.9	60
65	ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPbeta in CDH3 gene activation. <i>Human Molecular Genetics</i> , 2010 , 19, 2554-66	5.6	17
64	Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. <i>Human Molecular Genetics</i> , 2010 , 19, 943-52	5.6	81
63	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. <i>Journal of Medical Genetics</i> , 2010 , 47, 436-44	5.8	411
62	Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. <i>Gut</i> , 2010 , 59, 1516-26	19.2	42
61	Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. <i>Human Molecular Genetics</i> , 2010 , 19, 697-706	5.6	21
60	Pathology and genetics of familial gastric cancer. <i>International Journal of Surgical Pathology</i> , 2010 , 18, 33S-36S	1.2	13
59	KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. <i>Advances in Cancer Research</i> , 2010 , 109, 123-43	5.9	10
58	Germline CDH1 deletions in hereditary diffuse gastric cancer families. <i>Human Molecular Genetics</i> , 2009 , 18, 1545-55	5.6	159
57	KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. <i>Journal of Clinical Oncology</i> , 2009 , 27, 158-9; author reply 159	2.2	12

56	CDX2 promoter methylation is not associated with mRNA expression. <i>International Journal of Cancer</i> , 2009 , 125, 1739-42	7.5	10
55	The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. <i>International Journal of Cancer</i> , 2009 , 125, 2360-6	7.5	15
54	Hereditary gastric cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2009 , 23, 147-57	2.5	53
53	TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. <i>Familial Cancer</i> , 2009 , 8, 383-90	3	12
52	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. <i>Nature Genetics</i> , 2009 , 41, 365-70	36.3	317
51	Molecular cloning and analysis of SSc5D, a new member of the scavenger receptor cysteine-rich superfamily. <i>Molecular Immunology</i> , 2009 , 46, 2585-96	4.3	14
50	Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. <i>Gastroenterology</i> , 2009 , 136, 2137-48	13.3	128
49	PIK3CA Gene Alterations in Human Cancers 2009 , 1-20		
48	The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. <i>Oncogene</i> , 2008 , 27, 4255-60	9.2	68
47	Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. <i>International Journal of Gynecological Cancer</i> , 2008 , 18, 1234-47	3.5	10
46	BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. <i>BMC Cancer</i> , 2008 , 8, 255	4.8	105
45	B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. <i>Gastroenterology</i> , 2008 , 135, 899-906	13.3	54
44	Molecular targets and biological modifiers in gastric cancer. <i>Seminars in Diagnostic Pathology</i> , 2008 , 25, 274-87	4.3	23
43	Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. <i>Human Molecular Genetics</i> , 2008 , 17, 3566-76	5.6	58
42	BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. <i>Journal of Pathology</i> , 2008 , 214, 320-7	9.4	38
41	Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. <i>Journal of Pathology</i> , 2008 , 216, 295-306	9.4	105
40	Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. <i>Journal of Clinical Pathology</i> , 2008 , 61, 25-30	3.9	75
39	KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. <i>Oncogene</i> , 2007 , 26, 158-63	6.3	139

38	A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007 , 450, 619-26	5.1	11
37	Germline E-cadherin mutations in familial lobular breast cancer. <i>Journal of Medical Genetics</i> , 2007 , 44, 726-31	5.8	131
36	Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 2360-72	27.4	324
35	Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4231-8	2.2	57
34	Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 1061-7	3.6	37
33	Genetics, pathology, and clinics of familial gastric cancer. <i>International Journal of Surgical Pathology</i> , 2006 , 14, 21-33	1.2	120
32	E-cadherin missense mutations, associated with hereditary diffuse gastric cancer (HDGC) syndrome, display distinct invasive behaviors and genetic interactions with the Wnt and Notch pathways in <i>Drosophila</i> epithelia. <i>Human Molecular Genetics</i> , 2006 , 15, 1704-12	5.6	31
31	Expression of Lea in gastric cancer cell lines depends on FUT3 expression regulated by promoter methylation. <i>Cancer Letters</i> , 2006 , 242, 191-7	9.9	33
30	Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. <i>Journal of Medical Genetics</i> , 2006 , 43, 138-42	5.8	135
29	The prevalence of PIK3CA mutations in gastric and colon cancer. <i>European Journal of Cancer</i> , 2005 , 41, 1649-54	7.5	290
28	BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. <i>Oncogene</i> , 2005 , 24, 3995-8	9.2	128
27	Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. <i>Oncogene</i> , 2005 , 24, 7630-4	9.2	42
26	Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005 , 446, 181-4	5.1	37
25	Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. <i>Carcinogenesis</i> , 2005 , 26, 923-30	4.6	35
24	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. <i>Human Molecular Genetics</i> , 2004 , 13, 2303-11	5.6	102
23	Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. <i>Oncogene</i> , 2004 , 23, 2236-40	9.2	86
22	Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. <i>Genes Chromosomes and Cancer</i> , 2004 , 39, 138-42	5	73
21	E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. <i>European Journal of Cancer</i> , 2004 , 40, 1897-903	7.5	87

20	Genetic screening for familial gastric cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2004 , 2, 51-64	2.3	25
19	Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. <i>Journal of Human Genetics</i> , 2003 , 48, 183-9	4.3	13
18	MBD4 mutations are rare in gastric carcinomas with microsatellite instability. <i>Cancer Genetics and Cytogenetics</i> , 2003 , 145, 103-7		15
17	Promoter methylation of TGFbeta receptor I and mutation of TGFbeta receptor II are frequent events in MSI sporadic gastric carcinomas. <i>Journal of Pathology</i> , 2003 , 200, 32-8	9.4	46
16	BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. <i>Oncogene</i> , 2003 , 22, 9192-6	9.2	121
15	Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. <i>Gastroenterology</i> , 2003 , 125, 1282	13.3	20
14	E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. <i>Human Molecular Genetics</i> , 2003 , 12, 3007-16	5.6	68
13	Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. <i>European Journal of Cancer</i> , 2003 , 39, 1222-7	7.5	41
12	Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. <i>Human Molecular Genetics</i> , 2003 , 12, 575-82	5.6	145
11	Genetic screening for hereditary diffuse gastric cancer. <i>Expert Review of Molecular Diagnostics</i> , 2003 , 3, 201-15	3.8	43
10	Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. <i>Human Mutation</i> , 2002 , 19, 510-7	4.7	142
9	CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. <i>International Journal of Cancer</i> , 2002 , 101, 196-7	7.5	47
8	Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. <i>Laboratory Investigation</i> , 2002 , 82, 1319-26	5.9	80
7	Different types of epithelial cadherin alterations play different roles in human carcinogenesis. <i>Advances in Anatomic Pathology</i> , 2002 , 9, 329-37	5.1	5
6	E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. <i>Oncogene</i> , 2001 , 20, 1525-8	9.2	219
5	Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. <i>Gastroenterology</i> , 2001 , 121, 823-9	13.3	365
4	MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. <i>Laboratory Investigation</i> , 2000 , 80, 1915-23	5.9	41
3	Familial gastric cancer: overview and guidelines for management. <i>Journal of Medical Genetics</i> , 1999 , 36, 873-80	5.8	290

2	The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. <i>American Journal of Pathology</i> , 1998 , 153, 1211-9	5.8	136
1	CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients		1